NEUWAY Pharma

NEUWAY Pharma was a private German biotechnology company focused on delivering neuropharmaceuticals across the blood-brain barrier using its proprietary EnPC (Engineered Protein Capsules) platform. The company positioned EnPC as a protein-based drug-delivery technology for transporting mRNA, RNA and other biotherapeutic payloads into the central nervous system and other tissues. NEUWAY concentrated on severe orphan brain diseases and also pursued partnering opportunities around its delivery platform for broader CNS applications. Its disclosed internal pipeline appears to have remained preclinical, including NWP007 for progressive multifocal leukoencephalopathy, while the company also collaborated with WACKER on RNA-based CNS therapeutics. Recent secondary sources indicate the company is closed rather than active.